Division of Endocrinology, Department of Pediatrics, Emory University, Atlanta, GA, USA.
Division of Hematology/Oncology/BMT, Department of Pediatrics, Emory University, 2015 Uppergate Drive Northeast, 4(th) Floor, Atlanta, GA 30322, USA; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.
Endocrinol Metab Clin North Am. 2020 Dec;49(4):565-587. doi: 10.1016/j.ecl.2020.07.001. Epub 2020 Oct 13.
The 5-year survival rate for childhood cancer survivors is currently greater than 80% in developed countries. However, survivors may have an increased risk of endocrine toxicities from their tumors or their treatments. Although some endocrinopathies are apparent soon after cancer therapy completion, others manifest years later; therefore, long-term surveillance is crucial. This article reviews the association between cancer treatments and endocrine late effects. It also summarizes recommendations regarding surveillance for endocrine late effects and referrals to endocrinologists based on treatment exposures. In addition, this article provides special considerations for the treatment of endocrinopathies in survivors.
儿童癌症幸存者的 5 年生存率目前在发达国家大于 80%。然而，幸存者可能会因肿瘤或治疗而面临内分泌毒性的风险增加。尽管一些内分泌疾病在癌症治疗完成后很快就会显现，但其他疾病则会在多年后出现；因此，长期监测至关重要。本文综述了癌症治疗与内分泌迟发性效应之间的关系。它还总结了基于治疗暴露情况，对内分泌迟发性效应监测和转介至内分泌学家的建议。此外，本文还为幸存者内分泌疾病的治疗提供了特殊考虑。
Zotero 插件